Study: U.S. experiences rapid growth in specialty drug spending
Specialty drugs more than doubled as a share of retail fills for the overall U.S. population between 2010 and 2017, according to a study using various sources and published in Health Affairs, growing from 1% to 2.3%.
Despite representing a small percentage of overall prescriptions, spending on these drugs accounted for approximately half of the country’s total spending on retail, mail-order and provider-administered drugs in 2018; however, the study noted that the cost of these drugs are difficult to track due to the use of manufacturer rebates.
Net spending was divided at 31.5% for all retail and mail-order drugs for Medicare Part D, 37.8% for Medicaid and 43.6% of private drug spending.
Related News Articles
Headline
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to disclose…
Headline
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell…
Headline
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations.…
Headline
The White House released a health care plan Jan. 15 addressing drug prices, health insurance premiums and price transparency efforts. The plan includes…
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…